[1]
Mennini, F.S., Paoletti, M., Bini, C., Marcellusi, A., Falcone, M. and Andreoni, M. 2022. Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP). Global and Regional Health Technology Assessment. 9, 1 (Apr. 2022), 45–57. DOI:https://doi.org/10.33393/grhta.2022.2287.